Developing a CoMSIA Model for Inhibition of COX-2 by Resveratrol Derivatives
Overview
Authors
Affiliations
Design of selective cyclooxygenase-2 (COX-2) inhibitors is still a challenging task because of active site similarities between COX isoenzymes. To help with this issue, we tried to generate a 3D-QSAR (3 dimensional quantitative structure activity relationships) model that might reflect the essential features of COX-2 active sites. Compounds in a series of resveratrol derivatives inhibitors with reported biological activity against COX-2 were used to construct a predictive comparative molecular similarity indices (CoMSIA) model. A CoMSIA model with acceptable internal and external predictability was developed and employed to design new not yet synthesized molecules with improved activity and selectivity toward COX-2. Finally, molecular docking of the inhibitors in COX-2 active site demonstrated the possible ability of proposed compounds to inhibit COX-2, selectively.
Resveratrol ameliorates oxaliplatin-induced neuropathic pain via anti-inflammatory effects in rats.
Dong Z, Wang Y, Wan W, Wu J, Wang B, Zhu H Exp Ther Med. 2022; 24(3):586.
PMID: 35949346 PMC: 9353538. DOI: 10.3892/etm.2022.11523.
Zhou T, Zhang S, He C, Zhuang Q, Han P, Jiang S Theranostics. 2017; 7(5):1389-1406.
PMID: 28435473 PMC: 5399601. DOI: 10.7150/thno.17647.